Cancer Immunotherapies Conference

*Extended Earlybird Opportunity*

We are honouring the earlybird registration fee for all participants (Academic, Industry and Students). This exciting opportunity remains available until registration closes on 22nd January 2016. Don’t forget that our registration packages are inclusive of accommodation for 3 fixed nights (28,29 Feb and 01 Mar 2016), a fully inclusive 24 hour food and beverage package and Gala Dinner.

There has been a revolution in Cancer Immunotherapy in the past few years.  The realization that monoclonal antibodies interfering with regulatory pathways, such as CTLA4 and PD-1 can have profound clinical effects, has transformed the field.  But that is not the only advance.  There have been others in the field of Cancer vaccines, T cells transformed with anti-cancer receptors, inhibition of regulatory T cells, regulating the cancer matrix and so on.

In this conference, leaders in the field will review the current state of the art, and give an indication as to what the future holds.

Key Sessions

1. Do we understand check-point inhibitors?
2. Can we optimise cancer vaccines?
3. Has gene therapy come of age?
4. How scientific progress is leading to new approaches to cancer
5. Novel research

The pace of progress in this field is truly exciting and suggests that the era of toxic chemotherapy, with essentially no specificity for the target is finally coming to a close.  But much work remains to be done to tame cancer from being a life-threatening disease.  This has happened in recent years for HIV, based on appropriate combination therapy.  The potential of using more targeted therapy of cancer to convert from life threatening to a chronic disease is apparent.

Confirmed Speakers

Jim Allison (MDAnderson)
IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY:  NEW INSIGHTS, OPPORTUNITIES, AND PROSPECT FOR CURES

Nina Bhardwaj (Mount Sinai Hospital)

Vincenzo Cerundolo (Oxford University)
ABILITY OF AMINO ACID DEGRADING ENZYMES TO MODULATE CANCER SPECIFIC IMMUNE RESPONSES 

Shu-Hsia Chen (Mount Sinai Hospital)

Glenn Dranoff (DFCI)

Michael Dustin (Oxford University)

Ronald Germain (NIAID)
IMAGING IMMUNITY – USING DYNAMIC AND HIGHLY MULTIPLEX STATIC MICROSCOPY TO PROBE INNATE AND ADAPTIVE RESPONSES IN TISSUES 

Philip Greenberg (University of Washington)

Robert Hershberg (Celgene)

Carl June (University of Pennsylvania)

Alan Korman (Bristol-Myers Squibb)
ANTI-TUMOR ACTIVITY OF IMMUNOMODULATORY ANTIBODIES: ISOTYPE MATTERS

Ronald Levy (Stanford University)
IMMUNOTHERAPY OF CANCER: TREATING THE TUMOR AND TREATING THE HOST 

Tak Wah Mak (Ontario Cancer Institute)

Kees Melief (Netherlands Cancer Center)
COMBINATION IMMUNOTHERAPY OF DISEASES CAUSED BY HIGH RISK HUMAN PAPILLOMA VIRUS

Miriam Merad (Mount Sinai Hospital)

Bob Schreiber (University of Washington)

Pam (Padmanee) Sharma (MDAnderson)

Michael Shepard (Halozyme)
REMODELING THE TUMOR MICROENVIRONMENT TO MAKE ROOM FOR IMMUNOTHERAPY 

Cornelia Trimble (The Johns Hopkins Hospital)